Real-World study of iptacopan for PNH in russia ends early
NCT ID NCT07036718
First seen Dec 08, 2025 · Last updated May 07, 2026 · Updated 26 times
Summary
This study followed 6 adults with paroxysmal nocturnal hemoglobinuria (PNH) who were already taking iptacopan as part of their routine care in Russia. The goal was to see if the drug helped raise hemoglobin levels and reduce the need for blood transfusions over 6 to 12 months. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Syktyvkar, Komi, 167904, Russia
-
Novartis Investigative Site
Grozny, 364047, Russia
-
Novartis Investigative Site
Moscow, 129110, Russia
-
Novartis Investigative Site
Murmansk, 183047, Russia
-
Novartis Investigative Site
Yuzhno-Sakhalinsk, 693000, Russia
Conditions
Explore the condition pages connected to this study.